Related Experiment Video
Updated: Jun 18, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Surfactant in the preterm infant: what's going on
Carlo Dani1, Jacopo Barp, Elettra Berti
1Department of Surgical and Medical Critical Care, Section of Neonatology, Careggi University Hospital of Florence, Florence, Italy. cdani@unifi.it
Insights
Surfactant therapy reduces lung problems and death in premature infants. Natural surfactants and early treatment are most effective, with ongoing research into improved surfactant strategies for respiratory distress syndrome.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Biochemistry
Background:
- Surfactant administration is a cornerstone in managing respiratory distress syndrome (RDS) in preterm infants.
- Established benefits include reduced pneumothorax and mortality.
- Current clinical practice is evolving due to widespread antenatal steroid use and nasal continuous positive airway pressure (nCPAP).
Purpose of the Study:
- To review the current evidence on surfactant treatment strategies for preterm infants.
- To discuss the evolving role of surfactant prophylaxis versus rescue therapy.
- To explore future directions for enhancing surfactant therapy, particularly for preventing bronchopulmonary dysplasia (BPD).
Main Methods:
- Review of existing literature on surfactant therapy in neonatal respiratory distress.
- Analysis of clinical trial data comparing different surfactant types and treatment timings.
- Examination of the impact of antenatal steroids and nCPAP on RDS management.
Main Results:
- Natural surfactants demonstrate superior efficacy compared to synthetic alternatives.
- Early surfactant rescue treatment is more beneficial than delayed treatment.
- The indications for surfactant prophylaxis are being re-evaluated in light of modern RDS management.
Conclusions:
- Surfactant therapy remains critical for preterm infants with RDS, with a preference for natural surfactants and early intervention.
- The changing clinical landscape necessitates a re-evaluation of optimal surfactant strategies.
- Future research may focus on augmenting exogenous natural surfactants with anti-inflammatory and antioxidant agents to combat lung injury and prevent BPD.
Abstract:
Surfactant treatment has been demonstrated to decrease pneumothorax and mortality in preterm infants. Natural surfactants are better than synthetic surfactants. Early rescue treatment with surfactant is better than late treatment, whereas the role of surfactant prophylaxis is under re-evaluation due to the actual large diffusion of antenatal steroid and nasal continuous positive airway pressure treatment which have changed the clinical characteristics of preterm infants with respiratory distress syndrome. It is possible that in the next future anti-inflammatory and anti-oxidant properties of exogenous natural surfactants may be improved through their combination with adequate agents with the aim of counteracting the pathogenetic role of inflammatory and oxidative lung injury injuries in the development of brochopulmonary dysplasia.
Related Concept Videos
Breathing
Pulmonary Cycle: Exhalation
Factors Affecting Pulmonary Ventilation
Alveolar Surface Tension
The alveolar fluid lines the luminal surface of the alveoli and exerts a force called surface tension. This force is caused by the polar water molecules in the liquid being more strongly attracted to each...
Atelectasis II: Pathophysiology
Surface Active Agents
Micelles
